ClinicalTrials.gg

Program

fostemsavir

Also written as “BMS-663068”, “Fostemsavir” and “Fostemsavir 600 mg”.

Its studies are mostly in Infections · HIV Infections, led by GlaxoSmithKline.

Furthest: phase 3, since Feb 9, 201519 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline192 open or runningphase 3since Feb 9, 2015Nov 6, 2009Sep 14, 2032phase 3 · NCT07393659

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 6, 2009.

  1. May 13, 2014Phase 1 study in InfectionsNCT02138084 · 102 enrolled · United States
  2. Jun 12, 2014Phase 1 study in InfectionsNCT02164045 · 38 enrolled · United States
  3. Sep 5, 2014Phase 1 study in HIV InfectionsNCT02234882 · 50 enrolled
  4. Oct 27, 2014Phase 1 study in InfectionsNCT02277600 · 32 enrolled · United States
  5. Feb 9, 2015Phase 3 study in HIV InfectionsNCT02362503 · 371 enrolled · United States, Argentina, Australia and more
  6. May 20, 2015Phase 1 study in InfectionsNCT02467335 · 52 enrolled · United States
  7. Jun 16, 20152 phase 1 studies in InfectionsNCT02480894, NCT02480881
  8. Jul 22, 2015Phase 1 study in InfectionsNCT02508064 · 27 enrolled · United Kingdom
  9. Dec 21, 2015Phase 1 study in HIV InfectionsNCT02674581 · 30 enrolled · United States
  10. Jan 6, 20162 phase 1 studies in InfectionsNCT02666001, NCT02666053
  11. May 31, 2016Phase 1 study in InfectionsNCT02805556 · 36 enrolled · United Kingdom
  12. Jul 28, 2016Phase 1 study in InfectionsNCT02859259 · 14 enrolled · United States
  13. Feb 12, 2021Phase 1 study in HIV InfectionsNCT04757974 · 32 enrolled · United States
  14. Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda

Ahead

  1. Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Envelope polyprotein GP160 inhibitor; Envelope polyprotein GP160 inhibitor”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07393659HIV Infections · Romania, South Africa, Uganda3RecruitingSep 14, 2032197
NCT04757974HIV Infections · United States1CompletedJul 31, 202132
NCT02859259Infections · United States1CompletedAug 12, 201614
NCT02805556Infections · United Kingdom1CompletedMay 5, 201636
NCT02666053Infections · United States1CompletedFeb 22, 201672
NCT02666001Infections · United States1CompletedJun 29, 201632
NCT02674581HIV Infections · United States1CompletedMay 24, 201630
NCT02508064Infections · United Kingdom1CompletedNov 5, 201527
NCT02480881Infections · United States1CompletedJan 11, 201626
NCT02480894Infections · United States1CompletedSep 21, 2015112
NCT02467335Infections · United States1CompletedOct 3, 201552
NCT02362503HIV Infections · United States, Argentina, Australia and more3Active, not recruitingAug 18, 2016371
NCT02277600Infections · United States1CompletedJan 12, 201532
NCT02234882HIV Infections1CompletedOct 31, 201450
NCT02164045Infections · United States1CompletedJul 25, 201438
NCT02138084Infections · United States1CompletedJul 24, 2014102
NCT02063360Infections1CompletedMay 1, 201442
NCT01384734Infections · United States, Argentina, Colombia and more2CompletedFeb 18, 2013254
NCT01009814HIV Infections · Germany2CompletedJun 25, 201050

How it is read

Names in the registry

  • “BMS-663068”, 14 entries
  • “Fostemsavir”, 1 entry
  • “Fostemsavir 600 mg”, 1 entry
  • “Fostemsavir 200 mg”, 1 entry
  • “BMS-663068 400 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.